112 related articles for article (PubMed ID: 28122282)
1. Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101.
Chien WW; Niogret C; Jugé R; Lionnard L; Cornut-Thibaut A; Kucharczak J; Savina A; Salles G; Aouacheria A
Leuk Res; 2017 Apr; 55():41-48. PubMed ID: 28122282
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
[TBL] [Abstract][Full Text] [Related]
3. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Alduaij W; Ivanov A; Honeychurch J; Cheadle EJ; Potluri S; Lim SH; Shimada K; Chan CH; Tutt A; Beers SA; Glennie MJ; Cragg MS; Illidge TM
Blood; 2011 Apr; 117(17):4519-29. PubMed ID: 21378274
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.
Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C
Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500
[TBL] [Abstract][Full Text] [Related]
5. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
[TBL] [Abstract][Full Text] [Related]
7. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
Tobinai K; Klein C; Oya N; Fingerle-Rowson G
Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
[TBL] [Abstract][Full Text] [Related]
8. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Herter S; Herting F; Mundigl O; Waldhauer I; Weinzierl T; Fauti T; Muth G; Ziegler-Landesberger D; Van Puijenbroek E; Lang S; Duong MN; Reslan L; Gerdes CA; Friess T; Baer U; Burtscher H; Weidner M; Dumontet C; Umana P; Niederfellner G; Bacac M; Klein C
Mol Cancer Ther; 2013 Oct; 12(10):2031-42. PubMed ID: 23873847
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Ogura M; Tobinai K; Hatake K; Uchida T; Suzuki T; Kobayashi Y; Mori M; Terui Y; Yokoyama M; Hotta T
Cancer Sci; 2013 Jan; 104(1):105-10. PubMed ID: 23046388
[TBL] [Abstract][Full Text] [Related]
10. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.
Niederfellner G; Lammens A; Mundigl O; Georges GJ; Schaefer W; Schwaiger M; Franke A; Wiechmann K; Jenewein S; Slootstra JW; Timmerman P; Brännström A; Lindstrom F; Mössner E; Umana P; Hopfner KP; Klein C
Blood; 2011 Jul; 118(2):358-67. PubMed ID: 21444918
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
12. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.
Honeychurch J; Alduaij W; Azizyan M; Cheadle EJ; Pelicano H; Ivanov A; Huang P; Cragg MS; Illidge TM
Blood; 2012 Apr; 119(15):3523-33. PubMed ID: 22354003
[TBL] [Abstract][Full Text] [Related]
13. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab: a new class of anti-CD20 monoclonal antibody.
Gagez AL; Cartron G
Curr Opin Oncol; 2014 Sep; 26(5):484-91. PubMed ID: 25014645
[TBL] [Abstract][Full Text] [Related]
15. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
Salles G; Morschhauser F; Lamy T; Milpied N; Thieblemont C; Tilly H; Bieska G; Asikanius E; Carlile D; Birkett J; Pisa P; Cartron G
Blood; 2012 May; 119(22):5126-32. PubMed ID: 22431570
[TBL] [Abstract][Full Text] [Related]
18. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101.
Jak M; van Bochove GG; Reits EA; Kallemeijn WW; Tromp JM; Umana P; Klein C; van Lier RA; van Oers MH; Eldering E
Blood; 2011 Nov; 118(19):5178-88. PubMed ID: 21948297
[TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
20. Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies.
Grandjean CL; Montalvao F; Celli S; Michonneau D; Breart B; Garcia Z; Perro M; Freytag O; Gerdes CA; Bousso P
Sci Rep; 2016 Oct; 6():34382. PubMed ID: 27698437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
